Defending Cardiovascular Health: Cardiac Monitoring and Cardiac Rhythm Management Devices Market Set to Soar Past USD 274.52 Billion by 2030
The global Cardiac Monitoring and Cardiac Rhythm Management Devices market size is expected to reach USD 60.25 billion by 2030 and exhibit a CAGR of 6.6% in the forecast period (2023−2030), according to Skyquest’s latest research report. The increasing prevalence of cardiovascular diseases, growing ageing population worldwide, rising awareness about early detection and management of cardiac conditions, advancements in technology leading to improved monitoring and management devices, increasing demand for remote patient monitoring and home healthcare, expanding applications of cardiac monitoring in sports and fitness, favourable reimbursement policies for cardiac devices and procedures, are fueling the market’s growth.
Westford, USA, June 22, 2023 (GLOBE NEWSWIRE) — According to SkyQuest’s latest global research, increasing adoption of wearable cardiac monitoring devices, integration of artificial intelligence and machine learning in Cardiac Monitoring and Cardiac Rhythm Management Devices, rising demand for remote monitoring and telehealth solutions, development of implantable cardiac devices with advanced features, the emergence of wireless and smartphone-compatible cardiac monitoring technologies, focus on personalized medicine and patient-centric cardiac care, are the trends that aid in the market’s growth.
Get sample copy of this report:
Browse in-depth TOC on “Cardiac Monitoring and Cardiac Rhythm Management Devices Market”
- Pages – 242
- Tables – 62
- Figures – 75
Cardiac monitoring involves the continuous or periodic assessment of a patient’s heart function using specialized devices. Cardiac rhythm management devices, such as pacemakers and implantable cardioverter-defibrillators (ICDs), are implanted devices that help monitor and regulate abnormal heart rhythms, ensuring proper cardiac function and potentially preventing life-threatening situations.
Prominent Players in Cardiac Monitoring and Cardiac Rhythm Management Devices Market
- Amgen
- Genentech
- Biogen
- Gilead Sciences
- AbbVie
- Johnson & Johnson
- Roche
- Novartis
- Vertex Pharmaceuticals
- Celgene
- Sanofi
- Pfizer
- BioMarin Pharmaceutical
- Alnylam Pharmaceuticals
- Sarepta Therapeutics
- CRISPR Therapeutics
- Sangamo Therapeutics
Browse summary of the report and Complete Table of Contents (ToC):
https://www.skyquestt.com/report/cardiac-monitoring-and-cardiac-rhythm-management-devices-market
Cardiac Rhythm Management Devices Demand to Grow Substantially in the Forecast Period
Cardiac Rhythm Management devices dominated the global market as they are widely used for the management of arrhythmias and other cardiac rhythm disorders. These devices have demonstrated effectiveness in improving patient outcomes and have a well-established presence in the market.
Hospital and Clinics are the Leading Application Segment
In terms of application, the hospital and clinics segment is the leading segment due to the increasing demand. In addition, cardiac monitoring and rhythm management devices are extensively used in hospitals and clinics for the diagnosis, monitoring, and treatment of cardiac conditions.
North America is the leading Market Due to the Well-established Health Infrastructure
Region-wise, North America is one of the largest growing markets with a huge emphasis on healthcare Infrastructure. The regions have well-established healthcare infrastructure, advanced medical technology, and a high prevalence of cardiovascular diseases, contributing to their market dominance. North America, particularly the United States, has been at the forefront of technological advancements in the healthcare industry, including cardiac monitoring and rhythm management. The region benefits from strong research and development capabilities, favorable reimbursement policies, and a high adoption rate of innovative medical devices.
Speak to Analyst for your custom requirements:
A recent report thoroughly analyses the major players operating within the Cardiac Monitoring and Cardiac Rhythm Management Devices market. This comprehensive evaluation has considered several crucial factors, such as collaborations, mergers, innovative business policies, and strategies, providing invaluable insights into the key trends and breakthroughs in the market. Additionally, the report has carefully scrutinized the market share of the top segments and presented a detailed geographic analysis. Finally, the report has highlighted the major players in the industry and their ongoing endeavors to develop innovative solutions that cater to the ever-increasing demand for Cardiac Monitoring and Cardiac Rhythm Management Devices.
Key Developments in Cardiac Monitoring and Cardiac Rhythm Management Devices Market
- In March 2023, Abbott Laboratories acquired HeartStart, Inc. for $1.1 billion. HeartStart, Inc. is a privately held company that develops, and markets automated external defibrillators (AEDs). This acquisition will give Abbott Laboratories access to Heart Start’s technology, which could help Abbott Laboratories to expand its AED offerings.
Key Questions Answered in Cardiac Monitoring and Cardiac Rhythm Management Devices Market Report
- What specific growth drivers are projected to impact the market during the forecast period?
- Can you list the top companies in the market and explain how they have achieved their positions of influence?
- In what ways do regional trends and patterns differ within the global market, and how might these differences shape the market’s future growth?
Related Reports in SkyQuest’s Library:
Global Bowel Management Systems Market
Global Veterinary Oncology Market
Global Muscle Stimulator Market
Global Laparoscopic Devices Market
Global In-vitro Fertilization Microscopes Market
About Us:
SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.
Address:
1 Apache Way, Westford, Massachusetts 01886
Phone:
USA (+1) 617-230-0741
Email: sales@skyquestt.com
